Friday, 20 Sep 2019

You are here

PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.

This report describes the results of the first 52 weeks of PALACE 3, a randomized, controlled, phase 3 trial that included 505 PsA patients with psoriatic skin involvement.  All patients in the study met the Classification Criteria for Psoriatic Arthritis (CASPAR) and had ≥three swollen and ≥three tender joints. Prior treatment with conventional DMARDs and/or biologics was mandatory. Patients were also required to have active skin disease with ≥one plaque psoriasis skin lesion >2 cm in size.

At week 16, ACR 20 responses were superior to placebo (18%) in those receiving 20 mg bid (28%, p=0.0295) or 30 mg bid (41%, p<0.0001). This effect was sustained at week 52, with 56% of patients receiving apremilast 20 mg and 63% receiving apremilast 30 mg achieving an ACR20 response.

Despite low entry PASI scores (< 8), PASI-75 responses were significantly better in apremilast 20 mg and 30 mg patients versus placebo (placebo: 8%; 30 mg: 21%, p=0.0098; 20 mg: 20%, p=0.0215 at week 16).  PASI50 (49% and 55%) were seen in apremilast 20mg and 30 mg groups respectively and at week 52 the PASI75 was 29% and 39%, respectively.

Enthesitis score (MASES) did not reach statistical significance with mean changes of −0.9 for apremilast 20 mg, −1.1 for apremilast 30 mg and −0.7 for placebo at week 24.  

In terms of safety, no new safety signals were reported. Main side effects were diarrhoea, nausea, headache and upper respiratory tract infection. All side effects were mild or moderate in severity.

Study concluded that apremilast shows significant and sustained efficacy in following PsA domains: ACR20 response, changes in HAQ-DI, mean and mean per cent change in TJC, mean change in SJC, dactylitis count, and DAS-28 (CRP), achievement of DAS-28 (CRP) <2.6, physician's and patient's global assessments of disease activity, and skin involvement.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.